Here are some highlights from last week's earnings coverage from BloggingStocks:

• CBS Corp. (NYSE: CBS) reported that Q3 revenue was flat while earnings and cash flow declined.
• Clorox Co. (NYSE: CLX) reported better-than-expected Q1 earnings, helped by healthy gross margins.
• Comcast Corp. (NASDAQ: CMCSA) posted better-than-expected Q3 earnings with modest revenue growth.
• Dean Foods Co. (NYSE: DF) Q3 revenue missed estimates but earnings came in better than expected.
• Expeditors International of Washington Inc. (NASDAQ: EXPD) traded lower after its Q3 earnings miss.
• Garmin Ltd. (NASDAQ: GRMN) beat earnings estimates in the week after the Google Navigation launch.

While UBS (NYSE: UBS) remains the largest bank in Switzerland, this isn't helping much. In the company's latest quarterly results, there was a net loss of $552.9 million. Then again, UBS had to take some major charges, such as for the sale of its Brazilian investment bank and valuation changes on its large outstanding debts.

But there is more bad news: UBS continued to suffer from problems with its private banking division. Unfortunately, assets continue to flee (up to $25.8 billion in the prior quarter). The main reason is the U.S. crackdown on offshore tax havens, which has resulted in UBS handing over information on 4,450 accounts. Obviously, this is extremely chilling for client relationships.

In wealth management circles, Robert McCann is a pro. After all, he ran Merrill Lynch's financial advisory business -- known as the "thundering herd" -- which is now part of Bank of America (NYSE: BAC).

However, he left in January and wanted another opportunity. But there was a problem: he had a noncompete. So, with the help of skillful attorneys, he was able to reach some type of settlement.

What has Blackstone (NYSE: BX) been doing with all those theme parks it's been buying? Well, the answer is becoming a bit clearer now. The private equity firm is getting ready to take theme park operator Merlin Entertainments public early next year.

Several investment banks have already been called to advise on the transaction, including Citigroup (NYSE: C), Goldman Sachs (NYSE: GS), Deutsche Bank (NYSE: DB), UBS (NYSE: UBS), and Nomura (NYSE: NMR). If all goes as planned, the deal could be good for $3.33 billion.

According to The Hollywood Reporter, the advertising market could be ready for an upswing. Michael Morris, an analyst at UBS, is making a connection between improved sales at retail stores and a robust environment for commercials and the like. His reasoning is sound: if retail businesses are doing better, then they might want want to take advantage of new cash levels to invest in marketing initiatives aimed at bringing in traffic.

Indeed, the advertising industry has been in the dumps. Any good news is welcome. Media entities such as Disney (NYSE: DIS), Time Warner (NYSE: TWX), Viacom (NYSE: VIA), CBS (NYSE: CBS), News Corp. (NASDAQ: NWS), and General Electric's (NYSE: GE) NBC Universal, are counting on increased opportunities to sell their respective inventories at better prices.

Deutsche Bank (NYSE: DB) closed at $64.23. DB September option implied volatility is at 49, October is at 51; below its 26-week average of 66, according to Track Data, suggesting decreasing price movement.

Credit Suisse (NYSE: CS) closed at $47.94. CS October option implied volatility of 47 is below its 26-week average of 62 according to Track Data, suggesting decreasing price movement.

UBS AG (NYSE: UBS), Switzerland's biggest bank, closed at $17.02. UBS September option implied volatility is at 54, October is at 56; below its 26-week average of 70, according to Track Data, suggesting decreasing price movement.

Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com.

Going into its IPO, investors were expecting nice gains from Emdeon. Well, the company did not disappoint. Last night, the company priced 23.7 million shares at $15.50 (this was an 11% increase in the number of shares). It was at the top of its $13.50-$15.50 range.

Emdeon runs a sophisticated platform that connects payers, providers and patients in the US healthcare system (built over the past 25 years). Yes, in light of the proposed reforms from the Obama Administration, this is certainly an attractive space. After all, a big goal is to find ways to cut costs -- and technology should be a key.

It was not a good sign. Last night, Cumberland Pharmaceuticals priced its IPO at $17 a share, which was below the $19-$21 range. And, in light of this weakness, the stock is down 9 cents to $16.91 so far in today's trading.

Yet, Cumberland is a fairly solid company. Focused on specialty pharmaceuticals, it has several branded prescription products. The main target areas include: hospital acute care and gastroenterology.

A key differentiator is Cumberland's efficient direct sales model. In all, there are only 66 sales reps. Then again, because of Cumberland's laser focus, it is easier to target the market.

Analyst upgrades:

• UBS upgraded Wendy's/Arby's (NYSE: WEN) to Buy from Neutral and raised its target to $5.50 from $4.90 based on improving sales momentum at Wendy's and potential improvements at Arby's.
• Goldman upgraded 3M (NYSE: MMM) to Buy from Neutral and raised its target to $85 from $78. The firm cites 3M's short-cycle exposure and relative valuation for the upgrade.
• Thomas Weisel upgraded JCPenney (NYSE: JCP) to Market Weight from Underweight citing comfort in the company's intermediate-term recovery potential.
• UBS AG (NYSE: UBS) was upgraded to Buy from Hold at ING Group.
• Gap (NYSE: GPS) was upgraded to Overweight from Equal Weight at Barclays.
• Alliance Healthcare (NYSE: AIQ) was upgraded to Outperform from Market Perform at Wells Fargo.